Supernus Pharmaceuticals Inc (SUPN)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	2,769	36,892	26,559	55,010	60,716	27,654	57,058	76,969	73,175	110,817	134,568	150,543	168,648	169,867	156,746	152,282	147,487	145,342	142,123	133,233
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Pretax margin		0.46%	5.96%	4.14%	8.15%	9.02%	4.25%	9.23%	13.14%	13.07%	20.33%	24.40%	28.06%	33.28%	36.50%	37.46%	37.86%	37.55%	35.60%	34.74%	32.98%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $2,769K ÷ $605,106K
= 0.46%

The pretax margin of Supernus Pharmaceuticals Inc has shown some fluctuations over the past eight quarters. In Q1 2022, the company had a relatively high pretax margin of 12.80%, which then decreased in the following quarter to 9.06%. Subsequently, in Q3 2022, the pretax margin increased to 9.10%, before dropping in Q4 2022 to 4.20%. This downward trend continued into Q1 2023 with a pretax margin of 8.23%, followed by a further decline to 4.19% in Q2 2023. However, in Q3 2023, there was a notable increase in the pretax margin to 6.05%, which then rose slightly to 0.46% in Q4 2023.

Overall, the pretax margin of Supernus Pharmaceuticals Inc has been somewhat volatile, experiencing fluctuations in profitability over the past eight quarters. It may be beneficial for stakeholders to further investigate the reasons behind these changes to assess the company's financial performance and make informed decisions.